Uni-Bio Science Group Announces 2023 Interim Results
- Written by The Bulletin
Achieved Record High Profit of HK$39.4M
Driven by Scale-Up Operations and Remarkable Growth in Marketed Drugs
Expanding Multiple Channels and Diverse Commercialization for New Products
HONG KONG SAR - EQS Newswire - 28 August 2023 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2023 (the "Period").
Driven by Scale-Up Operations and Remarkable Growth in Marketed Drugs
Expanding Multiple Channels and Diverse Commercialization for New Products
HONG KONG SAR - EQS Newswire - 28 August 2023 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries referred to as the "Group", stock code: 0690.HK), is pleased to announce its interim results for the six months ended 30 June 2023 (the "Period").
Read more: Uni-Bio Science Group Announces 2023 Interim Results
